Exyn Technologies Secures $35M in Series B Funding
Penn spinout Exyn Technologies, a pioneer in multi-platform robotic autonomy for complex, GPS-denied environments, had a $35 million Series B round at the end of 2022.
Penn’s Abramson Cancer Center Presents New Cancer Research at 2022 American Society of Hematology (ASH) Annual Meeting
Researchers from Penn’s Abramson Cancer Center presented the preliminary results of an ongoing Phase I clinical trial for a novel CAR T therapy to be used after cancer.
Penn Researchers Work On Reducing CO2 Emissions by Repurposing Waste from Industrial Mines
Peter Psarras, a research assistant professor in chemical and biomolecular engineering, and his colleagues are repurposing waste from industrial mines.
Penn spinout Peroxitech raises $25M to advance novel drug to treat acute lung injury
Penn spinout Peroxitech raised $25M to further develop its novel drug candidate, PIP-2.
Nokia Bell Labs Prize: Prototype ferroelectric-diode-based memory device
Jariwala, Olsson and Stach’s first prize-winning proposal presents a prototype ferroelectric-diode-based memory device.
Penn Spinout Verismo Therapeutics Creates New R&D Facility in CIC on Market St
Verismo plans to use this space for its in-house translational research.
Penn Spinout Avisi Technologies Raises $4.06 Million in Seed Round To Be Used to Develop Glaucoma Treatment Device
Avisi was founded in 2017 by Penn students Rui Jing J., the company's CEO, and Brandon Kao and Adarsh Battu, who were studying business and engineering.
Vetigenics Founder Nicola Mason Featured on CBS 60 Minutes for Canine Cancer Research
Nicola Mason, BVetMed, PhD, of Penn Vet was featured on CBS' 60 Minutes, where she spoke about her research on immunotherapy treatment for cancer in dogs.
Avisi Technologies Closes $4 Million Seed Round to Further Develop Glaucoma Treatment Device
Penn spinout Avisi Technologies raised $4.06 million in a seed round led by Accanto Partners.
Penn Today Interviews John Swartley About PCI’s Impact
In the article, Swartley discusses some key highlights from FY22, including the major impact Penn technologies have made on patients.